A TAT-FXN fusion polypeptide useful in treating subjects diagnosed with Friedrich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.

Methods for the reversal of hemorrhagic shock or hemorrhagic trauma. Methods for restoring mean arterial pressure to a normal range and reducing trauma adverse risks in a patient through the administration of oxygen reduced blood compositions.

The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use as kallikrein inhibitors in therapy. ##STR00001##

This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10):

##STR00001##

as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

The present disclosure provides compositions comprising ephedrine sulfate ready for immediate use in a clinical setting, and methods of making and using same.

There are disclosed herein compositions comprising selepressin for use in treating sepsis in a patient. The composition comprising selepressin may be administered within six hours from when the patient requires vasopressor therapy. The patients may have a serum lactate concentration of less than about 2 mmol/L prior to treatment and/or a ratio of partial pressure arterial oxygen to fraction of inspired oxygen (PaO.sub.2/F.sub.iO.sub.2) of greater than about 200 prior to treatment. Related methods also are disclosed.

Methods and compositions of treating patients with metabolic syndrome or a disease associated with metabolic syndrome using inhibitors that target natural intraepithelial lymphocytes.

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.

A synchronized water is disclosed, in which all single water molecules at the same time are arranged in an identical way to a stable homogenous microstructure, wherein said synchronized water in a distilled condition and at atmospheric pressure has a) a density of from 0.997355 to 0.998836 g/ml at 220 C, b) a water temperature at the freezing point of from −6.7° C. to −8.2° C., c) a melting point of from 0.10 C to 0.20 C, d) a surface tension of from 72.3 to 72.7 dyn/cm at 220 C, and e) a dielectric constant of from 82.4 to 82.6 F/m, as well as a method for preparation thereof and different uses thereof.